QY Research Inc. (Global Market Report Research Publisher) announces the release of 2025 latest report “Drug Traceability Scanner- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2020-2024) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Drug Traceability Scanner market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Drug Traceability Scanner was estimated to be worth US$ 317 million in 2025 and is projected to reach US$ 553 million, growing at a CAGR of 8.4% from 2026 to 2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6090098/drug-traceability-scanner
Drug Traceability Scanner Product Introduction
The drug traceability scanner is a special device that integrates optical recognition, data processing and network communication functions. It is mainly used to read the traceability mark on the drug packaging (such as one-dimensional code, two-dimensional code or RFID tag that complies with the GS1 standard). By parsing the production batch number, expiration date, manufacturer, circulation path and other information contained in the mark, it can realize the traceability and supervision of the entire chain of drugs from production, warehousing, circulation to terminal sales. It usually supports offline storage and online real-time data upload, can be connected to the national drug traceability platform and the internal management system of the enterprise, and is widely used in drugstores, hospital pharmacies, drug wholesale enterprises and regulatory departments. By quickly verifying the authenticity of drugs and tracking circulation records, it provides key technical support for combating counterfeit and inferior drugs, ensuring drug safety, and meeting the requirements of the Drug Administration Law and other regulations.
According to the new market research report “Global Drug Traceability Scanner Market Report 2025-2031”, published by QYResearch, the global Drug Traceability Scanner market size is projected to reach USD 0.51 billion by 2031, at a CAGR of 8.4% during the forecast period.
Figure00001. Global Drug Traceability Scanner Market Size (US$ Million), 2025 VS 2031
Above data is based on report from QYResearch: Global Drug Traceability Scanner Market Report 2025-2031 (published in 2024). If you need the latest data, plaese contact QYResearch.
Figure00002. Global Drug Traceability Scanner Top 13 Players Ranking and Market Share (Ranking is based on the revenue of 2024, continually updated)
Above data is based on report from QYResearch: Global Drug Traceability Scanner Market Report 2025-2031 (published in 2024). If you need the latest data, plaese contact QYResearch.
According to QYResearch Top Players Research Center, the global key manufacturers of Drug Traceability Scanner include Soman Technology, Tiga Healthcare Technologies, iData, Urovo, ivysun, Rakinda, XTIOT, newland, Seuic, Xincode, etc. Drug Traceability Scanner manufacturing is mainly concentrated in East Asia (especially China) and parts of Southeast Asia, where strong electronics and barcode-imaging supply chains, high-density OEM/ODM manufacturing capacity, cost-effective embedded hardware and IoT module production, and close alignment with rapidly expanding pharmaceutical traceability policy implementation and retail healthcare digitization enable fast product iteration and large-scale deployment.
Table 1. Drug Traceability Scanner Industry Chain Analysis
| Item | Description | |
| Upstream | Core Component Suppliers | - High-Precision Scanning Module Suppliers: Manufacture 2D/QR code imaging modules with <0.3s scan speed, high recognition accuracy for damaged/wrinkled drug packaging codes, and compliance with GS1/ISO 15415 traceability code standards.
- Electronic Component Suppliers: Provide embedded microcontrollers, low-power memory chips, and power management units. - Communication Module Suppliers: Supply 4G/5G/Wi-Fi/Bluetooth modules to enable real-time uploads to national drug traceability platforms. |
| Raw Material & Structural Part Suppliers | - Casing Suppliers: Produce flame-retardant ABS+PC plastic casings with anti-scratch surface treatment for pharmacy/warehouse use.
- Internal Part Suppliers: Provide shock-absorbent silicone gaskets and corrosion-resistant metal brackets. |
|
| Midstream | Equipment manufacturers | Conduct pre-assembly component quality validation (e.g., 10,000+ scan accuracy tests); program custom firmware to support national drug traceability code standards (e.g., China’s GS1-compliant codes); perform GSP/GMP compliance testing (audit trail functionality, data encryption certification); package finished scanners with anti-vibration, electrostatic-protective materials for logistics |
| Downstream | Pharmaceutical Companies | Deploy scanners at production end-of-line stations (scan traceability codes to bind with batch numbers, expiry dates, and manufacturing locations in enterprise ERP systems); use in warehouse outbound processes (verify code consistency before shipping to distributors); integrate with serialization systems to meet regulatory traceability reporting requirements (e.g., submitting batch-level data to national drug authorities) |
| Pharmacies | Deploy at retail counters (scan drug packaging codes during checkout to query authenticity, production information, and circulation records via the national drug traceability collaborative platform); use for inventory management (scan codes to auto-update stock levels, flag expired drugs, and generate restock alerts); submit daily scanned sales data to local drug regulatory agencies to fulfill GSP compliance obligations |
Source: Secondary Sources, Press Releases, Expert Interviews and QYResearch, 2025
Table 2. Drug Traceability Scanner Industry Policy Analysis
| Policy | Description | |
| 1 | China: Updated Drug Traceability Management Measures (2024) | Mandates scanners to support moisture/dust-resistant scan modules (for cold-chain drug packaging); requires real-time data upload to the National Drug Traceability Platform (even in remote areas via 4G backup); and mandates 5+ years of audit trail retention for scanner operation records. |
| 2 | EU: FMD Enforcement & Scanner Accuracy Update (2023) | Enforces mandatory 99.9% recognition accuracy for scanners (including damaged/wrinkled drug codes); requires 72-hour offline data caching for scanners (to avoid disruptions in low-network areas); and mandates annual third-party validation of scanner performance. |
| 3 | U.S.: DSCSA Post-Serialization Compliance Rule (2024) | Requires scanners to integrate automated batch-data reconciliation (matching incoming/outgoing drug serial numbers); mandates AI-powered counterfeit code pattern detection (to flag tampered identifiers); and requires compatibility with FDA’s Drug Supply Chain Security System (DS3) for real-time reporting. |
Source: Secondary Sources, Press Releases, Expert Interviews and QYResearch, 2025
Table 3. Drug Traceability Scanner Industry Development Trends
| Development Trends | Description | |
| 1 | Multi-Technology Recognition Integration | Scanners are integrating 2D barcode/QR code, RFID, and even near-field communication (NFC) recognition capabilities — supporting global standards (GS1, DSCSA SPI) to adapt to diverse drug packaging formats (e.g., glossy blister packs, cold-chain RFID-tagged meds). This enables seamless scanning across high-value, cold-chain, and standard drug categories. |
| 2 | AI-Enhanced Intelligent Functionality | Scanners are embedded with AI algorithms for intelligent post-scan analysis: auto-detecting tampered/counterfeit codes (via pattern recognition), automating batch serial number reconciliation (matching incoming/outgoing drug stock), and triggering real-time alerts for expired/recalled drugs. This reduces manual compliance work for pharmacies and pharma firms. |
| 3 | Edge Computing & Offline-Online Synergy | Scanners adopt edge computing for local data processing (lowering network latency and data transmission pressure), paired with extended offline caching (72+ hours of scan records storage). Data is encrypted at the edge, and automatic sync with traceability platforms activates once network connectivity resumes — ideal for remote rural pharmacies or low-network logistics hubs. |
| 4 | Industry-Specific Environmental Adaptation | Scanners are customized for niche supply chain scenarios: cold-chain-resistant models (operating at -20°C to 5°C for refrigerated drugs), IP65+ dust/moisture-proof units (for warehouse logistics), and shock-resistant designs (for frequent handling in distribution centers). These adaptations meet regulatory requirements for stable performance across the drug supply chain’s harsh environments. |
Source: Secondary Sources, Press Releases, Expert Interviews and QYResearch, 2025
Table 4. Drug Traceability Scanner Industry Development Opportunities
| Development Opportunities | Description | |
| 1 | Rural & Remote Pharmacy Equipment Upgrading | Underpenetrated rural/remote pharmacy markets (e.g., in emerging economies) have growing demand for cost-effective, offline-capable traceability scanners — driven by regional policies mandating full drug traceability coverage, paired with government rural healthcare infrastructure funding to equip these under-resourced terminals. |
| 2 | Cold-Chain Drug Traceability Specialization | The expansion of cold-chain drug segments (biologics, vaccines, temperature-sensitive meds) creates demand for specialized scanners: models with -20°C to 5°C operating temperature resistance, integrated RFID for cold-chain tag reading, and sync capabilities with temperature-monitoring systems (aligned with regulatory cold-chain safety requirements). |
| 3 | Retail Pharmacy Digital System Integration | Chain pharmacies and modern retail terminals are upgrading to integrated digital operations (POS, inventory WMS, member systems) — creating opportunities for scanners that natively integrate with these platforms, enabling seamless post-scan data sync (automatic stock updates, compliance reporting) to reduce manual workload. |
| 4 | Global Cross-Standard Scanner Export | The spread of regional traceability mandates (EU FMD, U.S. DSCSA, Singapore NPTS) drives demand for scanners compatible with multiple international standards (GS1, DSCSA SPI, FMD 2D codes). Manufacturers can penetrate global markets by supplying multi-compliant, regulatory-validated scanner models. |
Source: Secondary Sources, Press Releases, Expert Interviews and QYResearch, 2025
Table 5. Drug Traceability Scanner Obstacles/Challenges to Industry Development
| Obstacles/Challenges | Description | |
| 1 | Fragmented Regional Regulatory & Standard Compatibility | Different global regions (EU, U.S., China) enforce distinct traceability code standards (e.g., FMD 2D barcodes, DSCSA SPIs, national unified codes) and compliance rules. Manufacturers must design scanners to support multiple standards, raising R&D costs, production complexity, and time-to-market for cross-regional models. |
| 2 | Cost Barriers for Small-Scale End-Users | Advanced scanners (with AI recognition, multi-technology support) carry high price points. Small independent pharmacies, rural clinics, and small pharma distributors (prevalent in emerging markets) face budget constraints, slowing full traceability coverage in under-resourced segments despite policy mandates. |
| 3 | Technical Limitations in Complex Packaging Scenarios | Drug packaging varies widely (glossy blister packs, cold-chain frosted bags, wrinkled cardboard) and codes may be damaged/worn. Ensuring ≥99.9% recognition accuracy across these scenarios (while maintaining durability in harsh environments like cold chains) requires continuous technical optimization, increasing manufacturing/calibration costs. |
| 4 | Data Security & Cross-Platform Interoperability Risks | Scanners transmit sensitive drug data (batch numbers, circulation records) across national traceability platforms, enterprise ERPs, and retail POS systems. Balancing end-to-end data encryption (to meet HIPAA/GSP standards) with seamless interoperability between disparate, protocol-incompatible systems poses persistent operational and technical challenges. |
Source: Secondary Sources, Press Releases, Expert Interviews and QYResearch, 2025
The report provides a detailed analysis of the market size, growth potential, and key trends for each segment. Through detailed analysis, industry players can identify profit opportunities, develop strategies for specific customer segments, and allocate resources effectively.
The Drug Traceability Scanner market is segmented as below:
By Company
Soman Technology
Tiga Healthcare Technologies
iData
Urovo
ivysun
Rakinda
XTIOT
newland
Seuic
Xincode
Superlead
Dingyu Iot
Xindeli Tech
Deli
Segment by Type
Stationary Scanner
Handheld Scanner
Segment by Application
Pharmaceutical Companies
Hospitals Pharmacies
Pharmacies
Others
Each chapter of the report provides detailed information for readers to further understand the Drug Traceability Scanner market:
Chapter 1: Introduces the report scope of the Drug Traceability Scanner report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. (2021-2032)
Chapter 2: Detailed analysis of Drug Traceability Scanner manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. (2021-2026)
Chapter 3: Provides the analysis of various Drug Traceability Scanner market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. (2021-2032)
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.(2021-2032)
Chapter 5: Sales, revenue of Drug Traceability Scanner in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world..(2021-2032)
Chapter 6: Sales, revenue of Drug Traceability Scanner in country level. It provides sigmate data by Type, and by Application for each country/region.(2021-2032)
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. (2021-2026)
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Benefits of purchasing QYResearch report:
Competitive Analysis: QYResearch provides in-depth Drug Traceability Scanner competitive analysis, including information on key company profiles, new entrants, acquisitions, mergers, large market shear, opportunities, and challenges. These analyses provide clients with a comprehensive understanding of market conditions and competitive dynamics, enabling them to develop effective market strategies and maintain their competitive edge.
Industry Analysis: QYResearch provides Drug Traceability Scanner comprehensive industry data and trend analysis, including raw material analysis, market application analysis, product type analysis, market demand analysis, market supply analysis, downstream market analysis, and supply chain analysis.
and trend analysis. These analyses help clients understand the direction of industry development and make informed business decisions.
Market Size: QYResearch provides Drug Traceability Scanner market size analysis, including capacity, production, sales, production value, price, cost, and profit analysis. This data helps clients understand market size and development potential, and is an important reference for business development.
Other relevant reports of QYResearch:
Global Drug Traceability Scanner Market Outlook, In‑Depth Analysis & Forecast to 2032
Global Drug Traceability Scanner Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
Global Drug Traceability Scanner Market Research Report 2026
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 19 years of experience and a dedicated research team, we are well placed to provide useful information and data for your business, and we have established offices in 7 countries (include United States, Germany, Switzerland, Japan, Korea, China and India) and business partners in over 30 countries. We have provided industrial information services to more than 60,000 companies in over the world.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
Email: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
